52 Week Range
As of on the Korea Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Celltrion Inc Q2 Consolidated Operating Profit 182 Billion Won, Up 118% From Year Earlier
Celltrion Healthcare Says European Commission Grants Marketing Authorisation For Remsima SC Formulation
Celltrion Launches Human Clinical Trial Of Potential Covid-19 Antiviral Antibody Treatment Following Positive Pre-Clinical Results
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment is mainly engaged in the development, production and sale of biosimilar products. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio and chemical drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main merchants sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs, anti-malignant tumor drugs, and other merchants. The Company sells its products in domestic and overseas markets such as Europe and the United States.
Biotechnology & Drugs
23, Academy-ro, Yeonsu-gu
Jung Jin Seo
Chairman of the Board
Woo Sung Kee
Chief Executive Officer, Director
Sin Jae Jang
Senior Vice President
Jeong Won Yoon
Senior Vice President
Sang Jun Lee
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
South Korea's Celltrion Inc on Thursday said British regulators had given it regulatory approval for a phase I clinical trial of its experimental COVID-19 treatment drug.
South Korea on Friday approved an early stage clinical trial of Celltrion Inc's experimental COVID-19 treatment drug, making it the country's first such antibody drug to be tested on humans.
Takeda Pharmaceutical Co Ltd <4502.T> has agreed to sell a portfolio of over-the-counter and prescription drugs marketed in the Asia Pacific region to South Korea's Celltrion Inc <068270.KS> for $278 million, it said on Thursday
Takeda Pharmaceutical Co Ltd said on Thursday it will divest some over-the-counter and prescription drugs sold exclusively in Asia Pacific to South Korea's Celltrion Inc.
South Korea expects clinical trials of Celltrion Inc's experimental COVID-19 treatment to begin in Europe next month and aims to secure sizable supplies of the drug by the first half of next year, a senior health official said on Tuesday.
South Korea's Celltrion Inc said on Monday its experimental treatment of COVID-19 demonstrated an up to 100-fold reduction in viral load of the disease in animal testing, saying it aims to start in-human clinical trials in late July.
South Korea's Celltrion Inc said on Monday its experimental treatment of COVID-19 demonstrated a 100-fold reduction in viral load of the disease in animal testing.
* CELLTRION COMPLETES NEUTRALISATION TEST ON CANDIDATE MONOCLONAL ANTIBODIES (MABS) FOR COVID-19 ANTIVIRAL ANTIBODY TREATMENT
* CELLTRION ACCELERATES DEVELOPMENT OF COVID-19 ANTIVIRAL TREATMENT AND AIMS TO LAUNCH RAPID SELF-TESTING KIT
* CELLTRION INC: Q4 OPERATING PROFIT 114 BILLION WON, UP 160% FROM A YEAR AGO Further company coverage: (Reporting by Joyce Lee)
South Korean drugmaker Celltrion Inc <068270.KS> aims to set up a joint venture in China within the first half of this year, and begin selling products in the country next year, its chairman said on Sunday.
The U.S. Food and Drug Administration on Friday approved South Korean drugmaker Celltrion Inc's biosimilar to Roche Holding AG's blockbuster breast cancer treatment, Herceptin.
* CELLTRION INC RECEIVES FDA APPROVAL FOR HERZUMA, A HERCEPTIN BIOSIMILAR - FDA WEBSITE Source text - https://bit.ly/2vAmAqr Further company coverage:
Celltrion Inc's Truxima on Wednesday became the first biosimilar to Roche Holding AG's $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin's lymphoma.
An advisory panel to the U.S. Food and Drug Administration on Wednesday voted unanimously in favor of Celltrion Inc's copycat drug of Roche Holding AG's blood cancer drug Rituxan.
Celltrion Pharm Inc's biosimilar of Roche Holding AG's blockbuster cancer drug, Rituxan, on Wednesday won unanimous backing from an advisory panel to the U.S. Food and Drug Administration.
* Says it signs 157.8 billion won contract to provide products
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.